SBC Medical: Reacceleration and AI-Driven Fee Upside Signal Inflection

After two years of restructuring, SBC returns to double-digit growth with AI-enabled fee increases and a clear path to 1,000 clinics.

SBC · Earnings Call · 2026-08-13

Inflection Point

"It is the quarter in which we completed the structural reforms we undertook in 2025, and SBC's growth entered a phase of reacceleration." This line from the AI-led presentation sets the tone: SBC Medical delivered Q2 revenue of $49M (up 13% y/y) and adjusted EBITDA of $20M (up 32%), with margins expanding to 41%. Profit growth outpaced revenue, driven by higher management services revenue and a revision of service fees. The company is clearly emerging from a two-year downturn in the Japanese aesthetic medicine market, where competition had intensified sharply. “we grew both revenue and profit despite a weaker yen... The main driver was higher management services revenue, reflecting the expansion of the points business following the change in our operating policy in June 2025.” — Unknown Attendee, Analyst · 2026-08-13 The number of locations reached 287 (up 34 y/y) and annual customer visits hit 6.92 million, up 10%. Same-clinic revenue rose 6% and average spend per visit increased 9%—both volume and unit price moving up together. This is a fundamental shift from the stagnant growth of 2024-25.

AI as the Next Competitive Moat

Management is positioning AI as the central pillar of their growth strategy. They are deploying chatbot, AI interpreter, marketing AI, and a call center AI, with a clear focus on improving clinic economics. CFO Yuya Yoshida quantified the upside: "Specifically... Gorilla Clinic starting from July and call center revision starting from July... together about $15 million per year on a full year basis." (inline quote)

We are releasing various AI products one after another. As Dr. Aikawa explained, chatbot has been released in August. And before the end of the year, we expect to open AI call center and AI preceptor to support the training of nurse concierge will also be launched. So in the next 6 months to 12 months, we will be introducing more AI products and core system will be revamped using AI.
Yuya Yoshida, CFO, COO and AI Evangelist · 2026-08-13

The strategic emphasis on aesthetic health care is now broadening: the mix is still ~84% aesthetic, 16% non-aesthetic, but the company has established a dedicated non-aesthetic team and explicitly targets orthopedics, ophthalmology, and fertility treatment. CEO Aikawa stated, "In 10 years' time, the proportion of aesthetic health care is expected to be smaller, while other categories will be much larger." This evolution aligns with the longevity theme, which they aim to own in Japan.

Financial Strength and Shareholder Value

SBC holds $127M in effective net cash, which is roughly 45% of its market cap. The company has ample dry powder to execute its multi-brand and international expansion plans, while also highlighting a rapidly broadening shareholder base (up 4.7x y/y). They are actively investing in AI and global initiatives, but also returning value through disciplined capital allocation. “Before we became public under our group, we have Rize Clinics and Gorilla Clinics... total turnover was about JPY 25 billion... it has increased to JPY 33 billion... growth was achieved.” — Yuya Yoshida, CFO, COO and AI Evangelist · 2026-08-13 US expansion via OrangeTwist is progressing with a new CEO and shared operational know-how. The company is also testing an asset-light "powered by SBC" model in Thailand, with plans to scale across ASEAN. The stock has shown a recent +9.3% move over the last 6 days, though the company remains a small-cap ($331M). The direction is clear, but the valuation re-rating depends on execution of the 1,000-clinic vision by 2035. This is a credible inflection story, backed by numbers and a clear strategic pivot. The AI-driven fee upside is a company-unique catalyst that is not yet fully reflected in consensus estimates. If they can sustain the reacceleration, the market should reward it.